Skip to main content

A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease.

Publication ,  Journal Article
Hankins, JS; Brambilla, D; Potter, MB; Kutlar, A; Gibson, R; King, AA; Baumann, AA; Melvin, C; Gordeuk, VR; Hsu, LL; Nwosu, C; Porter, JS ...
Published in: Blood Adv
December 12, 2023

Hydroxyurea reduces sickle cell disease (SCD) complications, but medication adherence is low. We tested 2 mobile health (mHealth) interventions targeting determinants of low adherence among patients (InCharge Health) and low prescribing among providers (HU Toolbox) in a multi-center, non-randomized trial of individuals with SCD ages 15-45. We compared the percentage of days covered (PDC), labs, healthcare utilization, and self-reported pain over 24 weeks of intervention and 12 weeks post-study with a 24-week preintervention interval. We enrolled 293 patients (51% male; median age 27.5 years, 86.8% HbSS/HbSβ0-thalassemia). The mean change in PDC among 235 evaluable subjects increased (39.7% to 56.0%; P < 0.001) and sustained (39.7% to 51.4%, P < 0.001). Mean HbF increased (10.95% to 12.78%; P = 0.03). Self-reported pain frequency reduced (3.54 to 3.35 events/year; P = 0.041). InCharge Health was used ≥1 day by 199 of 235 participants (84.7% implementation; median usage: 17% study days; IQR: 4.8-45.8%). For individuals with ≥1 baseline admission for pain, admissions per 24 weeks declined from baseline through 24 weeks (1.97 to 1.48 events/patient, P = 0.0045) and weeks 25-36 (1.25 events/patient, P = 0.0015). PDC increased with app use (P < 0.001), with the greatest effect in those with private insurance (P = 0.0078), older subjects (P = 0.033), and those with lower pain interference (P = 0.0012). Of the 89 providers (49 hematologists, 36 advanced care providers, 4 unreported), only 11.2% used HU Toolbox ≥1/month on average. This use did not affect change in PDC. Tailoring mHealth solutions to address barriers to hydroxyurea adherence can potentially improve adherence and provide clinical benefits. A definitive randomized study is warranted. This trial was registered at www.clinicaltrials.gov as #NCT04080167.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood Adv

DOI

EISSN

2473-9537

Publication Date

December 12, 2023

Volume

7

Issue

23

Start / End Page

7190 / 7201

Location

United States

Related Subject Headings

  • Telemedicine
  • Pain
  • Medication Adherence
  • Male
  • Hydroxyurea
  • Humans
  • Female
  • Anemia, Sickle Cell
  • Adult
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hankins, J. S., Brambilla, D., Potter, M. B., Kutlar, A., Gibson, R., King, A. A., … Shah, N. (2023). A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease. Blood Adv, 7(23), 7190–7201. https://doi.org/10.1182/bloodadvances.2023010670
Hankins, Jane S., Donald Brambilla, Michael B. Potter, Abdullah Kutlar, Robert Gibson, Allison A. King, Ana A. Baumann, et al. “A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease.Blood Adv 7, no. 23 (December 12, 2023): 7190–7201. https://doi.org/10.1182/bloodadvances.2023010670.
Hankins JS, Brambilla D, Potter MB, Kutlar A, Gibson R, King AA, et al. A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease. Blood Adv. 2023 Dec 12;7(23):7190–201.
Hankins, Jane S., et al. “A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease.Blood Adv, vol. 7, no. 23, Dec. 2023, pp. 7190–201. Pubmed, doi:10.1182/bloodadvances.2023010670.
Hankins JS, Brambilla D, Potter MB, Kutlar A, Gibson R, King AA, Baumann AA, Melvin C, Gordeuk VR, Hsu LL, Nwosu C, Porter JS, Alberts NM, Badawy SM, Simon J, Glassberg JA, Lottenberg R, DiMartino L, Jacobs S, Fernandez ME, Bosworth HB, Klesges LM, Shah N. A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease. Blood Adv. 2023 Dec 12;7(23):7190–7201.

Published In

Blood Adv

DOI

EISSN

2473-9537

Publication Date

December 12, 2023

Volume

7

Issue

23

Start / End Page

7190 / 7201

Location

United States

Related Subject Headings

  • Telemedicine
  • Pain
  • Medication Adherence
  • Male
  • Hydroxyurea
  • Humans
  • Female
  • Anemia, Sickle Cell
  • Adult
  • 3201 Cardiovascular medicine and haematology